


Listeriosis Market Analysis 2034: FDA Approvals, Clinical Trials, Therapies, and Companies by DelveInsight

Listeriosis companies are Emergent Bio Solutions, Pfizer, GlaxoSmithKline, Zydus Cadila, Aurobindo Pharma, Teva Pharmaceutical, Fresenius Kabi, Novartis, more

ALBANY, NEW YORK, UNITED STATES, July 8, 2024 /EINPresswire.com/ --DelveInsight's "Listeriosis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an indepth understanding of Listeriosis, historical and forecasted epidemiology



as well as the Listeriosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Listeriosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Listeriosis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Listeriosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Listeriosis market.

Request for a Free Sample Report @ Listeriosis Market Forecast

Some facts of the Listeriosis market report are:

- According to DelveInsight, Listeriosis market size is expected to grow at a decent CAGR by 2034.
- Leading Listeriosis companies working in the market are Emergent Bio Solutions Inc, Pfizer Inc, LimmaTech Biologics AG, GlaxoSmithKline plc, Zydus Cadila, Bionpharma, Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Fresenius Kabi AG, Novartis AG, WOCKHARDT, Mylan N.V., LUPIN, Sun Pharmaceutical Industries Ltd, Novel Laboratories Inc., Hainan Poly Co. Ltd, Amneal Pharmaceuticals LLC and others.
- The increase in the number of people suffering from listeriosis infection treatment market across the globe acts as one of the major factors driving the growth of listeriosis infection

treatment market.

- Although, lack of novel disease specific treatment and low healthcare budget in some developing countries are expected to obstruct the market growth.
- The MONALISA-GENBIO study is a national case-control prospective study on listeriosis. It aims to identify human genetic susceptibility factors to listeriosis and evaluate biomarkers for diagnosis and prognosis. The study collects clinical and biological data from patients with listeriosis and includes controls with comparable backgrounds.
- On August 11, 2023, in conjunction with regional and local partners, Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) are looking into a listeria monocytogenes infection outbreak that may be related to Real Kosher Ice Cream of Brooklyn, New York's Soft Serve On The Go ice cream cups.
- On May 12, 2022, following the treatment of Listeria monocytogenes-infected cells with ampicillin, researchers noticed intracellular production of antibiotic-resistant Listeria monocytogenes L-forms. The findings reported here give compelling evidence that antibiotic administration to infected host cells can cause intracellular Listeria monocytogenes to produce L-forms. Furthermore, these findings imply that intracellular L-forms remain inside host cells indicating that they represent live, still-growing, proliferating bacteria.

Listeriosis Overview

Listeriosis is a bacterial infection caused by the bacterium Listeria monocytogenes. While it primarily affects pregnant women, newborns, elderly individuals, and those with weakened immune systems, it can also impact healthy individuals. The bacterium is commonly found in soil, water, and some animal products, including unpasteurized dairy products and raw meats. Symptoms of listeriosis can vary but often include fever, muscle aches, nausea, diarrhea, and gastrointestinal symptoms. In severe cases, the infection can lead to meningitis, septicemia, or miscarriage in pregnant women.

Diagnosis typically involves blood or cerebrospinal fluid cultures to identify the presence of Listeria monocytogenes. Treatment usually consists of antibiotics, such as ampicillin or penicillin, although antibiotic resistance can complicate therapy.

Prevention strategies include practicing good food safety habits, such as thoroughly cooking meat and washing fruits and vegetables, as well as avoiding unpasteurized dairy products and deli meats unless heated to a safe temperature. Pregnant women and individuals with weakened immune systems should take extra precautions to minimize their risk of exposure.

Prompt medical attention is crucial for individuals suspected of having listeriosis, particularly those at higher risk of severe complications. Public health efforts also focus on surveillance, outbreak investigation, and education to prevent and control listeriosis infections.

Learn more about Listeriosis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/listeriosis-

market?utm source=einpresswire&utm medium=pressrelease&utm campaign=apr

The Listeriosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Listeriosis market trends by analyzing the impact of current Listeriosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Listeriosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Listeriosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Listeriosis market in 7MM is expected to witness a major change in the study period 2020-2034.

Listeriosis Epidemiology

The Listeriosis epidemiology section provides insights into the historical and current Listeriosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Listeriosis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Listeriosis Epidemiology @ <u>Listeriosis Prevalence</u>

Listeriosis Drugs Uptake

This section focuses on the uptake rate of the potential Listeriosis drugs recently launched in the Listeriosis market or expected to be launched in 2020-2034. The analysis covers the Listeriosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Listeriosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Listeriosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Listeriosis Pipeline Development Activities

The Listeriosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Listeriosis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Listeriosis pipeline development activities @ https://www.delveinsight.com/report-store/listeriosis- market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Listeriosis Therapeutics Assessment

Major key companies are working proactively in the Listeriosis Therapeutics market to develop

novel therapies which will drive the Listeriosis treatment markets in the upcoming years are Emergent Bio Solutions Inc, Pfizer Inc, LimmaTech Biologics AG, GlaxoSmithKline plc, Zydus Cadila, Bionpharma, Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Fresenius Kabi AG, Novartis AG, WOCKHARDT, Mylan N.V., LUPIN, Sun Pharmaceutical Industries Ltd, Novel Laboratories Inc., Hainan Poly Co. Ltd, Amneal Pharmaceuticals LLC and others.

Learn more about the emerging Listeriosis therapies & key companies @ <u>Listeriosis Clinical Trials</u> and FDA Approvals

Listeriosis Report Key Insights

- 1. Listeriosis Patient Population
- 2. Listeriosis Market Size and Trends
- 3. Key Cross Competition in the Listeriosis Market
- 4. Listeriosis Market Dynamics (Key Drivers and Barriers)
- 5. Listeriosis Market Opportunities
- 6. Listeriosis Therapeutic Approaches
- 7. Listeriosis Pipeline Analysis
- 8. Listeriosis Current Treatment Practices/Algorithm
- 9. Impact of Emerging Therapies on the Listeriosis Market

Table of Contents

- 1. Key Insights
- 2. Executive Summary
- 3. Listeriosis Competitive Intelligence Analysis
- 4. Listeriosis Market Overview at a Glance
- 5. Listeriosis Disease Background and Overview
- 6. Listeriosis Patient Journey
- 7. Listeriosis Epidemiology and Patient Population
- 8. Listeriosis Treatment Algorithm, Current Treatment, and Medical Practices
- 9. Listeriosis Unmet Needs
- 10. Key Endpoints of Listeriosis Treatment
- 11. Listeriosis Marketed Products
- 12. Listeriosis Emerging Therapies
- 13. Listeriosis Seven Major Market Analysis
- 14. Attribute Analysis
- 15. Listeriosis Market Outlook (7 major markets)
- 16. Listeriosis Access and Reimbursement Overview
- 17. KOL Views on the Listeriosis Market
- 18. Listeriosis Market Drivers
- 19. Listeriosis Market Barriers
- 20. Appendix
- 21. DelveInsight Capabilities
- 22. Disclaimer

About DelveInsight

Delvelnsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Ankit Nigam
DelveInsight Business Research
+1 469-945-7679
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
Other

This press release can be viewed online at: https://www.einpresswire.com/article/725585500

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.